Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S83-S84
DOI: 10.1055/s-0044-1785401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Thomas A. Wadden und 12 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
What is the effect of tirzepatide on bodyweight reduction after a successful intensive lifestyle intervention?
Methods
SURMOUNT-3 is a double-blind, placebo-controlled trial in which adults with body mass index ≥30 kg/m^2 or ≥27 kg/m^2 and at least one obesity-related complication were enrolled. After a 12-week intensive lifestyle intervention (ILI), participants who achieved a weight reduction of ≥5% were randomized to the maximum tolerated dose (MTD) of tirzepatide (10 or 15 mg) or placebo once weekly for 72 weeks (n=579). The coprimary endpoint was to demonstrate that tirzepatide MTD is superior to placebo from randomization to week 72 in terms of percent body weight change and proportion of participants with ≥5% weight reduction. The efficacy estimand was used to assess efficacy which represented the average treatment effect, prior to treatment discontinuation.
Results
SURMOUNT-3 met the coprimary endpoint. The mean percentage weight change from randomization to week 72 was -21.1% with tirzepatide and 3.3% with placebo (on top of an average weight change of -6.9% after 12-week ILI). The percentage of participants achieving additional weight reduction ≥5% was 94.4% with tirzepatide and 10.7% with placebo. Furthermore, 98.6% of participants treated with tirzepatide MTD maintained ≥80% of weight reduction achieved during the ILI lead-in period. The most common adverse events with tirzepatide were gastrointestinal, generally being mild to moderate in severity.
Conclusion
Tirzepatide provided substantial additional reduction in bodyweight in participants who had achieved ≥5.0% weight reduction with intensive lifestyle intervention. ^ denotes square root for this submission Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., Forrester, T., & Lindner, U. (2024). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Diabetologie und Stoffwechsel, 19(S 01 S 01), S83-S84. https://doi.org/10.1055/s-0044-1785401
Vancouver
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S83-S84. doi:10.1055/s-0044-1785401
BibTeX
@article{Wadden2024,
author = {Wadden, Thomas A. and Chao, Ariana M. and Machineni, Sriram and Kushner, Robert and Ard, Jamy and Srivastava, Gitanjali and Halpern, Bruno and Zhang, Shuyu and Chen, Jiaxun and Bunck, Mathijs C. and Ahmad, Nadia Nazir and Forrester, Tammy and Lindner, Uwe},
title = {Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S83--S84},
doi = {10.1055/s-0044-1785401}
}
EUVIMED